Cordis and BrosMed launched ceremony for the localization strategy in China and will continue to uphold the mutual original commitment to innovation, maintain a patient-centered philosophy, persistently cultivate in the field of vascular intervention, and convey care to vascular disease patients worldwide.
The 37th Annual Meeting of the European Society for Vascular […]
This certification confirms BrosMed’s compliance with the high standards and regulatory requirements of most leading countries in the world.
BrosMed POT PTCA balloon is the world’s first dedicated balloon for proximal optimization technique (POT) and distal optimization technique (DOT) in bifurcation stenting.
Tiche™ 0.035” High Pressure PTA Balloon Dilatation Catheter is designed for the treatment of severely calcified peripheral vascular disease and challenging AV cases.
Rokku exchange device is dedicated to facilitate interventional medical device exchanges without losing wire position, and maximize the efficiency of complex cases during PCI procedures.
Tiche™ 0.035” PTA Balloon Dilatation Catheter has received the 510(k) clearance from the U.S. Food & Drug Administration on July 20, 2022.
To our clients, candidates and team members – thank you for coming on this journey with us. Your support makes Brosmed what it is today.
Thank you for visiting our booth and Let’s looking forward to meet at next MEDICA 2022!
POT™ PTCA balloon catheter received CE mark approval
Pronavi™ Microcatheter received CE mark approval
Guangdong ,China [May 24 , 2021] – Brosmed Ltd. today […]
